1-May-2026
Globe Newswire (Mon, 27-Apr 4:30 PM ET)
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
Globe Newswire (Mon, 20-Apr 4:30 PM ET)
CVRx Reports Preliminary First Quarter 2026 Financial Results
Globe Newswire (Mon, 13-Apr 8:00 AM ET)
Business Wire (Tue, 17-Mar 4:00 PM ET)
Business Wire (Tue, 17-Mar 2:44 PM ET)
Business Wire (Tue, 17-Mar 2:41 PM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Globe Newswire (Tue, 3-Mar 3:36 PM ET)
Globe Newswire (Mon, 2-Mar 8:30 AM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Globe Newswire (Tue, 24-Feb 5:31 PM ET)
Business Wire (Thu, 19-Feb 2:25 PM ET)
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
CVRX trades on the NASDAQ stock market under the symbol CVRX.
As of May 1, 2026, CVRX stock price climbed to $7.97 with 340,756 million shares trading.
CVRX has a beta of 1.73, meaning it tends to be more sensitive to market movements. CVRX has a correlation of 0.05 to the broad based SPY ETF.
CVRX has a market cap of $209.70 million. This is considered a Small Cap stock.
Last quarter CVRX reported $16 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $326,684 and missed earnings estimates by -$.03.
In the last 3 years, CVRX traded as high as $33.14 and as low as $4.30.
The top ETF exchange traded funds that CVRX belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
CVRX has underperformed the market in the last year with a return of +9.3%, while SPY returned +30.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CVRX shares. However, CVRX has outperformed the market in the last 3 month and 2 week periods, returning +16.4% and +8.3%, while SPY returned +4.4% and +1.5%, respectively. This indicates CVRX has been having a stronger performance recently.
CVRX support price is $7.10 and resistance is $7.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CVRX shares will trade within this expected range on the day.
